Extended Data Fig. 10: Frequency, reactivity and efficacy of tumor-reactive TCRs.
From: Sensitive identification of neoantigens and cognate TCRs in human solid tumors
a, Heatmaps reporting the frequencies of antigen-specific TCRβ clonotypes from patients 2, 5 and 6 within the different bulk TIL populations (top). TCRs are detailed in Supplementary Table 5. Antitumor-reactivity of TCR-transfected primary CD8 T cells, measured by 4-1BB upregulation following co-culture with autologous tumor cells (bottom). The background levels of 4-1BB expressed by cognate negative controls (TCR-T cells alone) were subtracted (Supplementary Fig. 4). b, Representative example of flow cytometry data showing in vitro tumor recognition (4-1BB upregulation) of antigen-specific TCRs (MAGEC1 TCRs A and B and SCM1AL674S TCR C) from patient 1. (MOCK: control of transfection, neg pair: irrelevant TCRα/β pair). c, In vivo efficacy of adoptively-transferred tyrosinase508-514 TCR-transduced T cells against autologous patient-derived tumor xenografts. The graph shows tumor size of individual hIL-2 NOG mice adoptively-transferred with TCR-transduced (in orange; n = 7) and untransduced (in blue; n = 5) cells. ACT was performed on Day 14.
